Exscientia plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EXAI research report →
Companywww.exscientia.ai
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates.
- CEO
- David Hallett
- IPO
- 2021
- Employees
- 483
- HQ
- Oxford, GB
Price Chart
Valuation
- Market Cap
- $633.18M
- P/E
- -3.07
- P/S
- 23.49
- P/B
- 1.25
- EV/EBITDA
- -1.60
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -36.48%
- Op Margin
- -876.56%
- Net Margin
- -726.94%
- ROE
- -34.85%
- ROIC
- -35.37%
Growth & Income
- Revenue
- $20.08M · -25.13%
- Net Income
- $-145,963,000 · -25.04%
- EPS
- $-1.18 · -22.92%
- Op Income
- $-176,004,000
- FCF YoY
- -76.27%
Performance & Tape
- 52W High
- $4.84
- 52W Low
- $4.84
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.83
- Avg Volume
- 0
Get TickerSpark's AI analysis on EXAI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our EXAI Coverage
We haven't published any research on EXAI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EXAI Report →